Zhijun Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhijun Han has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Luo Zhao
Department of Thoracic Surgery, Peking Union Medical College Hospital, CAMS & PUMC, Beijing, China, pumch.cn
2 shared publications Dongjie Ma
Department of Thoracic Surgery, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, People's Republic of China
1 shared publicationHongsheng Liu
Department of Thoracic Surgery, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, People's Republic of China
1 shared publication- Jia He
Department of Neurology The Third People's Hospital of Longgang District Shenzhen Shenzhen China
1 shared publication - Jiwei Li
Department of Thoracic Surgery, Zhengzhou Key Laboratory for Surgical Treatment for End-stage Lung Disease, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou 450003, P.R. China
1 shared publication - Li Li
State Key Laboratory of Multi-organ Injury Prevention and Treatment, Department of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 30 June 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (10) , 1536-1550
LncRNA H19 aggravates primary graft dysfunction after lung transplantation via KLF5-mediated activation of CCL28
- 30 June 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (10) , 1536-1550
Open AccessLncRNA H19 aggravates primary graft dysfunction after lung transplantation via KLF5-mediated activation of CCL28
- Open Access
- 7 October 2020
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 134 (7) , 857-858
Video-assisted thoracic resection of a rare ectopic mediastinal bronchial artery aneurysm
- 7 October 2020
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 134 (7) , 857-858
Open AccessVideo-assisted thoracic resection of a rare ectopic mediastinal bronchial artery aneurysm
- Open Access
- 1 May 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 3851-3858
Thoracoscopic Surgery to Treat Lung Metastases from Refractory Choriocarcinoma
Purpose: To assess the use of video-assisted thoracoscopic surgery to treat lung metastases from refractory choriocarcinoma. Patients and Methods: We reviewed patients diagnosed with refractory choriocarcinoma who underwent lung resection by video-assisted thoracoscopic surgery combined with chemotherapy between October 2013 and August 2019 at the Peking Union Medical College Hospital. The surgical records, pathologic findings and survival rates were analyzed. Results: The study included 73 patients who underwent 78 thoracoscopic surgeries. Most patients underwent lobectomy (48.7%), and 17 patients (21.8%) underwent resection of more than one lobe. The median operation time and bleeding volume were 95 minutes and 50 mL, respectively. The median duration of chest tube use and hospital stay were 3 days and 4 days, respectively. Postoperative complications were documented in 6 patients (7.7%). The thoracic lymph nodes were harvested in 51 patients (65.4%), but none of these patients had positive nodes. A total of 69.2% of the patients had positive pathologic findings. The mean follow-up time was 30 months. During follow-up, 11 patients experienced disease relapse, and 2 of them died because of brain metastasis. The overall disease-free rate was 83.6%, and the survival rate was 97.0% after excluding those lost to follow-up. Patients with decreased postoperative β-hCG showed a higher disease-free rate during follow up (P< 0.05). Conclusion: The minimally invasive video-assisted thoracoscopic approach is a valuable and safe treatment for refractory choriocarcinoma patients with lung metastases. Lymphadenectomy is not suggested for these patients. Patients with decreased postoperative β-hCG levels may achieve a much better prognostic result.
- 1 May 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 3851-3858
Open AccessThoracoscopic Surgery to Treat Lung Metastases from Refractory Choriocarcinoma
Purpose: To assess the use of video-assisted thoracoscopic surgery to treat lung metastases from refractory choriocarcinoma. Patients and Methods: We reviewed patients diagnosed with refractory choriocarcinoma who underwent lung resection by video-assisted thoracoscopic surgery combined with chemotherapy between October 2013 and August 2019 at the Peking Union Medical College Hospital. The surgical records, pathologic findings and survival rates were analyzed. Results: The study included 73 patients who underwent 78 thoracoscopic surgeries. Most patients underwent lobectomy (48.7%), and 17 patients (21.8%) underwent resection of more than one lobe. The median operation time and bleeding volume were 95 minutes and 50 mL, respectively. The median duration of chest tube use and hospital stay were 3 days and 4 days, respectively. Postoperative complications were documented in 6 patients (7.7%). The thoracic lymph nodes were harvested in 51 patients (65.4%), but none of these patients had positive nodes. A total of 69.2% of the patients had positive pathologic findings. The mean follow-up time was 30 months. During follow-up, 11 patients experienced disease relapse, and 2 of them died because of brain metastasis. The overall disease-free rate was 83.6%, and the survival rate was 97.0% after excluding those lost to follow-up. Patients with decreased postoperative β-hCG showed a higher disease-free rate during follow up (P< 0.05). Conclusion: The minimally invasive video-assisted thoracoscopic approach is a valuable and safe treatment for refractory choriocarcinoma patients with lung metastases. Lymphadenectomy is not suggested for these patients. Patients with decreased postoperative β-hCG levels may achieve a much better prognostic result.